TG Therapeutics (TGTX) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 1 Phase 1[2].
Trial NCT04130997[4] evaluates Ublituximab in Relapsing Multiple Sclerosis (RMS) with a target enrollment of 1100 participants. Trial NCT05877963[5] evaluates Ublituximab in Relapsing Multiple Sclerosis with a target enrollment of 800 participants. Trial NCT07211633[6] evaluates Ublituximab in Relapsing Multiple Sclerosis with a target enrollment of 360 participants.
No Form 4 insider filings for TGTX were recorded at the SEC in the past 30 days[7].